- cafead   Aug 09, 2024 at 11:32: AM
via With Gilead Sciences on the verge of an FDA decision for its liver disease drug seladelpar, the company has paid Johnson & Johnson $320 million to exit an 18-year-old licensing agreement on the compound.
article source
article source